CombinatoRx, Incorporated-Derived Combination Drug Candidate, Prednisporin, Acquired by Sanofi-Aventis K.K. Through Proposed Acquisition of Fovea Pharmaceuticals

Published: Oct 05, 2009

CAMBRIDGE, Mass.--(BUSINESS WIRE)--CombinatoRx, Incorporated (NASDAQ: CRXX), today announced that its ophthalmic collaborator, Fovea Pharmaceuticals SA, has entered into a proposed acquisition with Sanofi-Aventis. A CombinatoRx-derived combination drug candidate, Prednisporin, (FOV1101), which is a fixed dose combination of prednisolone and cyclosporine, is the most advanced product asset in the Fovea pipeline, with Phase 2b clinical studies planned for the treatment of persistent allergic conjunctivitis.

Back to news